News Brilique boosted by NICE’s long-term prevention recommendati... Recommendation will add to growth trajectory
News AZ's key drug Brilique fails in stroke trial Disappointment for AstraZeneca and key growth driver
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
